BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26903519)

  • 1. Use of Positron Emission Tomography to Detect Recurrence and Associations With Survival in Patients With Lung and Esophageal Cancers.
    Healy MA; Yin H; Reddy RM; Wong SL
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26903519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of ¹⁸F-fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma.
    Yasuda T; Higuchi I; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Hatazawa J; Doki Y
    Ann Surg Oncol; 2012 Feb; 19(2):652-60. PubMed ID: 21769466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Has integrated 18F FDG PET/CT improved staging, reduced early recurrence or increased survival in oesophageal cancer?
    Torrance AD; Almond LM; Fry J; Wadley MS; Lyburn ID
    Surgeon; 2015 Feb; 13(1):19-33. PubMed ID: 24206935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
    Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
    J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endoscopic ultrasonography in esophageal cancer leads to improved survival rates: results from a population-based study.
    Wani S; Das A; Rastogi A; Drahos J; Ricker W; Parsons R; Bansal A; Yen R; Hosford L; Jankowski M; Sharma P; Cook MB
    Cancer; 2015 Jan; 121(2):194-201. PubMed ID: 25236485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
    Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
    JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
    Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
    Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007.
    Dinan MA; Curtis LH; Carpenter WR; Biddle AK; Abernethy AP; Patz EF; Schulman KA; Weinberger M
    Radiology; 2013 Jun; 267(3):807-17. PubMed ID: 23418003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management.
    Marcus C; Paidpally V; Antoniou A; Zaheer A; Wahl RL; Subramaniam RM
    J Nucl Med; 2015 Feb; 56(2):204-8. PubMed ID: 25613535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.
    You JJ; Wong RK; Darling G; Gulenchyn K; Urbain JL; Evans WK
    J Thorac Oncol; 2013 Dec; 8(12):1563-9. PubMed ID: 24389439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET and PET-CT in esophageal and gastric cancer.
    Wieder HA; Krause BJ; Herrmann K
    Methods Mol Biol; 2011; 727():59-76. PubMed ID: 21331929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-D-glucose positron emission tomography.
    Lai CH; Huang KG; See LC; Yen TC; Tsai CS; Chang TC; Chou HH; Ng KK; Hsueh S; Hong JH
    Cancer; 2004 Feb; 100(3):544-52. PubMed ID: 14745871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.